The future of cutaneous T-cell lymphoma treatment

Larisa Geskin, MD of Columbia University Medical Center, New York, NY discusses the future of the treatment of cutaneous T-cell lymphoma (CTCL) at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. According to Dr Geskin, traditional chemotherapy will give way to targeted therapies and here is a focus on genetic abnormalities and pathway abnormalities in order to find targets. In the future, CTCL will be treated with a personalized approach using antibodies or small molecules.